ONA Therapeutics
Business Services · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Carrer De Baldiri Reixac Pcb Parc Cientí...Website
www.ona-therapeutics.comRevenue
$8.7 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ONA Therapeutics
Ona Therapeutics is a biotechnology company focused on developing first-in-class antibody drug conjugates (ADCs) aimed at treating advanced cancer. The company collaborates with leading academics and clinicians to identify novel therapeutic targets from the unique biology of treatment-refractory cancer patients. Their innovative approach combines biological expertise with advanced engineering techniques to create precision ADCs and antibody therapies. Ona Therapeutics primarily serves patients with advanced cancer who have limited treatment options, striving to provide effective new therapies for this challenging patient population.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ONA Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when ONA Therapeutics launches new products
Click to see if ONA Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once ONA Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at ONA Therapeutics
Check out if ONA Therapeutics is spiking on competitors!
ONA Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if ONA Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ONA Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
ONA Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ONA Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ONA Therapeutics.
ONA Therapeutics financials insights
Gather financial insights about ONA Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Seed
$1.7M
2020
Series A
$33.9M
2026
Series B
$86.6M
ONA Therapeutics Tech Stack
A closer look at the technologies used by ONA Therapeutics
Most Recent Scoops
Funding
Funding
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Partnership
Partnership, Product Development, Product Management, Intellectual Property, Sales Development
ONA Therapeutics News & Media
Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona's transition to a...REVEAL GENOMICS and Ona Therapeutics Join Forces to Advance Next-generation Cancer Treatment
BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS and Ona Therapeutics today announced a strategic collaboration aimed at accelerating the clinical development of ONA-255, a next-generation ADC designed to enhance the precision and efficacy of cancer treatment across multiple tumor types. ONA-255 is positioned to be a first-in-class molecule against a novel ADC target present in multiple, prevalent solid tumor types. Ona has privileged insight of the target as a hallmark of molecular adaptatioOna Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types
Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of...Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors
BARCELONA, Spain, Dec. 18, 2023 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ONA Therapeutics
Sign Up For FreeTo access detailed company insights
Ona Therapeutics is a biotechnology company focused on developing first-in-class antibody drug conjugates (ADCs) aimed at treating advanced cancer. The company collaborates with leading academics and clinicians to identify novel therapeutic targets from the unique biology of treatment-refractory cancer patients. Their innovative approach combines b... Read More
